Headache and Migraine

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 17, 2020.

After first-step data suggested that one small molecule CGRP receptor antagonist and a monoclonal antibody against CGRP were successful and safe together in migraine. One of the study authors, Kathleen Mullin, MD, discussed the data.

Biohaven’s small molecule CGRP receptor antagonist rimegepant has displayed safety and efficacy in a small cohort of patients with migraine using it alongside erenumab.

Those achieving ≥50% response attained migraine reductions nearly double that of the full cohort, with data possibly providing context for setting realistic patient expectations regarding the spectrum of response.

Neurology News Network for the week ending January 11, 2020.

New 52-week data from an extension study has suggested that recently FDA-approved ubrogepant (Ubrelvy; Allergan) is safe and tolerable, with minimal treatment-related adverse events with 2 doses assessed.

The guidelines included a review of 23 studies, suggesting that patients with normal neurological examinations do not require neuroimaging assessments as part of migraine treatment.

The oral, dual-mechanism therapy from Axsome Therapeutics met both of its primary end points in the phase 3 MOMENTUM trial in acute migraine, and is expected to be filed with the FDA.

Lasmiditan was efficacious across a number of doses in patients with migraine regardless of prior good or insufficient response to triptan administration.

With a differential diagnosis that varies from patient to patient, identifying and treating vestibular migraine continues to challenge even the most experienced clinicians.

The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.

The director of the Jefferson Headache Center at Thomas Jefferson University detailed the most notable achievements from 2019, and what to expect in the coming year.

Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.

Catch up on some of our most popular video interviews with leaders in the field, including discussions with Imad Najm, MD, James Leverenz, MD, Richard Isaacson, MD, and more.

Branded as Ubrelvy, Allergan’s oral calcitonin gene-related peptide antagonist is the first-in-class to be approved for this indication.

The third generation, high-affinity, selective small molecule CGRP receptor antagonist was significantly superior in the 2 higher doses on both co-primary end points of pain freedom and most bothersome symptoms.

A standardized treatment protocol in emergency departments lead to significant reductions in headache pain.

Treatment with the calcitonin gene-related peptide (CGRP) inhibitor resulted in significant improvements in monthly migraine headache days across the groups assessed, including a significantly greater number of patients with ≥50% and ≥75% reductions.

Although there are gaps in knowledge, investigators see potential in telemedicine for other neurologic disorders beyond stroke.

Results of the phase 3 ACHIEVE I trial showed a high percentage of patients were free from their most bothersome symptoms 2 hours post dose.

The anti-CGRP treatment from Teva was associated with reductions in the use of migraine-specific headache medication, migraine-associated symptoms, and any acute headache medication use compared to placebo.

With Theranica’s Nerivio Migra acute migraine device named a top invention of the year, three experts in migraine shared their insight into its clinical application in the early days of its availability, with varying experiences.

Neurology News Network for the week ending November 23, 2019.

The investigational new drug application for OWP Pharmaceuticals’ first-ever liquid formulation of topiramate, intended to offer a new delivery alternative for the therapy in epilepsy and migraine treatment, has been approved.

An analysis of ACHIEVE II suggests that the oral CGRP antagonist from Allergan provides significant pain freedom and relief of the most bothersome symptoms for adults with migraine for at least one dose assessed.